
## **Gregory R Fulcher**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1812164/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial. Diabetes Care, 2014, 37, 2084-2090.	8.6	93
2	Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review. Diabetes Research and Clinical Practice, 2018, 140, 118-128.	2.8	71
3	The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys. Journal of Medical Economics, 2014, 17, 751-761.	2.1	47
4	Large-for-Gestational-Age Neonates in Type 1 Diabetes and Pregnancy: Contribution of Factors Beyond Hyperglycemia. Diabetes Care, 2018, 41, 1821-1828.	8.6	46
5	Amount and Type of Dietary Fat, Postprandial Glycemia, and Insulin Requirements in Type 1 Diabetes: A Randomized Within-Subject Trial. Diabetes Care, 2020, 43, 59-66.	8.6	39
6	Factors associated with patient activation in an Australian population with comorbid diabetes and chronic kidney disease: a cross-sectional study. BMJ Open, 2017, 7, e017695.	1.9	38
7	Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3638-e3649.	3.6	37
8	Challenges of diabetes management during the <scp>COVID</scp> â€19 pandemic. Medical Journal of Australia, 2020, 213, 56.	1.7	34
9	Predictors of Health-Related Quality of Life in Patients with Co-Morbid Diabetes and Chronic Kidney Disease. PLoS ONE, 2016, 11, e0168491.	2.5	33
10	Self-management in patients with diabetes and chronic kidney disease is associated with incremental benefit in HRQOL. Journal of Diabetes and Its Complications, 2017, 31, 427-432.	2.3	24
11	Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Therapeutic Advances in Chronic Disease, 2015, 6, 375-388.	2.5	23
12	Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placeboâ€controlled, doubleâ€blind pilot clinical trial. International Wound Journal, 2015, 12, 422-427.	2.9	22
13	Association Between Glycemic Variability, HbA1c, and Large-for-Gestational-Age Neonates in Women With Type 1 Diabetes. Diabetes Care, 2017, 40, e98-e100.	8.6	18
14	HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment. BMJ Open, 2019, 9, e033059.	1.9	16
15	Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. Journal of the American Society of Nephrology: JASN, 2020, 31, 2446-2456.	6.1	15
16	Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes. Diabetes Research and Clinical Practice, 2016, 116, 96-99.	2.8	14
17	Activated protein C to heal pressure ulcers. International Wound Journal, 2016, 13, 986-991.	2.9	14
18	ldentification of Patients With Diabetes Who Benefit Most From a Health Coaching Program in Chronic Disease Management, Sydney, Australia, 2013. Preventing Chronic Disease, 2017, 14, E21.	3.4	13

**GREGORY R FULCHER** 

#	Article	IF	CITATIONS
19	Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial. Cardiovascular Research, 2022, 118, 1103-1114.	3.8	13
20	Routine glucose assessment in the emergency department for detecting unrecognised diabetes: a cluster randomised trial. Medical Journal of Australia, 2019, 211, 454-459.	1.7	12
21	The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study. PLoS ONE, 2019, 14, e0219685.	2.5	11
22	Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines. Diabetes, Obesity and Metabolism, 2020, 22, 1961-1975.	4.4	11
23	What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres. Diabetes Research and Clinical Practice, 2015, 108, 405-413.	2.8	10
24	Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study. BMJ Open, 2016, 6, e008203.	1.9	10
25	Outcomes for Women with Gestational Diabetes Treated with Metformin: A Retrospective, Case-Control Study. Journal of Clinical Medicine, 2018, 7, 50.	2.4	9
26	Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2019, 33, 63-68.	2.3	9
27	Suboptimal behaviour and knowledge regarding overnight glycaemia in adults with type 1 diabetes is common. Internal Medicine Journal, 2018, 48, 1080-1086.	0.8	6
28	Evaluation of the performance and outcomes for the first year of a diabetes rapid access clinic. Medical Journal of Australia, 2016, 205, 172-172.	1.7	5
29	Updated risk factors should be used to predict development of diabetes. Journal of Diabetes and Its Complications, 2017, 31, 859-863.	2.3	5
30	Patient reported barriers are associated with low physical and mental well-being in patients with co-morbid diabetes and chronic kidney disease. Health and Quality of Life Outcomes, 2018, 16, 215.	2.4	5
31	Plasma protein C levels are directly associated with better outcomes in patients with severe burns. Burns, 2019, 45, 1659-1672.	1.9	4
32	ARISE—a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design. Endocrine, 2021, 74, 530-537.	2.3	4
33	Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with TypeÂ2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries. Advances in Therapy, 2022, 39, 3735-3748.	2.9	3
34	Comment on Ooi and Wong. Twin Pregnancy With Gestational Diabetes Mellitus: A Double Whammy? Diabetes Care 2018;41:e15–e16. Diabetes Care, 2018, 41, e67-e67.	8.6	2
35	Utility of the Hospital Admission Risk Programme diabetes risk calculator in identifying patients with type 2 diabetes at risk of unplanned hospital presentations. Internal Medicine Journal, 2018, 48, 1198-1205.	0.8	1
36	Early protein C activation is reflective of burn injury severity and plays a critical role in inflammatory burden and patient outcomes. Burns, 2022, 48, 91-103.	1.9	1

**GREGORY R FULCHER** 

#	Article	IF	CITATIONS
37	A co-designed integrated kidney and diabetes model of care improves mortality, glycaemic control and self-care. Nephrology Dialysis Transplantation, 2022, 37, 1472-1481.	0.7	1
38	Continuous subcutaneous insulin infusion alters microRNA expression and glycaemic variability in children with type 1 diabetes. Scientific Reports, 2021, 11, 16656.	3.3	1
39	Women with type 2 diabetes in pregnancy remain a high-risk group. Minerva Endocrinology, 2018, 43, 224-225.	1.1	1
40	Prevention of cardiovascular disease: an evidenceâ€based clinical aid. Medical Journal of Australia, 2004, 180, 197-198.	1.7	0
41	Epidermal Protein C Levels Correspond to Local Injury Severity and Increased Clinical Support in Burn Patients. European Journal of Burn Care, 2021, 2, 226-237.	0.8	0